Sunday 18 October 2026
Export KYTX’s income statement to Excel — free account
Kyverna Therapeutics, Inc.
KYTX Healthcare Biotechnology
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million. In the quarter to June 2026, EPS grew 35.1%, free cash flow fell 27.1% and total debt rose 95,603.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.67
0.30
−5.03%
Follow KYTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(70.82%) | (64.67%) | (74.55%) | (87.24%) | |
| (61.17%) | (53.91%) | (60.42%) | (68.40%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(112.70%) | (65.04%) | (73.29%) | (82.48%) | |
Free Cash Flow per Share |
(3.64) | (3.48) | (2.49) | (2.61) | |
Free Cash Flow |
(157.82) | (154.18) | (150.39) | (158.98) | |
Capital Expenditures |
(0.57) | (0.47) | — | (0.23) | |
| Other line items | |||||
Cash ROIC |
(48.85%) | (28.75%) | (32.92%) | (40.78%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(2,350.49) | (347.29) | (144.82) | (88.74) | |
Operating CF/Net income |
0.98 | 0.95 | 0.96 | 1.04 | |
Depreciation/Fixed assets |
1.11 | 1.16 | 1.23 | 1.18 | |
Capex/Depreciation |
(0.29) | (0.26) | 0.00 | (0.15) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.62) | (3.47) | (2.49) | (2.61) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates